Merck moves into mRNA space with Moderna alliance

Moderna Therapeutics, the subject of the largest ever biotech private equity fundraising of $450m earlier this month (scripintelligence.com, 6 January 2015), has signed a license and collaboration agreement with Merck & Co for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).